Analytical Data
-
基因名
EBNA1BP2
- Application
-
别名
EBNA1BP2；EBP2;Probable rRNA-processing Protein EBP2
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q99848
-
表达区间
1-306aa
-
氨基酸序列
MGSSHHHHHH SSGLVPRGSH MGSMDTPPLS DSESESDESL VTDRELQDAF SRGLLKPGLN VVLEGPKKAV NDVNGLKQCL AEFKRDLEWV ERLDVTLGPV PEIGGSEAPA PQNKDQKAVD PEDDFQREMS FYRQAQAAVL AVLPRLHQLK VPTKRPTDYF AEMAKSDLQM QKIRQKLQTK QAAMERSEKA KQLRALRKYG KKVQTEVLQK RQQEKAHMMN AIKKYQKGFS DKLDFLEGDQ KPLAQRKKAG AKGQQMRKGP SAKRRYKNQK FGFGGKKKGS KWNTRESYDD VSSFRAKTAH GRGLKRPGKK GSNKRPGKRT REKMKNRTH
-
分子量
37 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
EBNA1BP2, or Epstein-Barr Virus Nuclear Antigen 1 Binding Protein 2, is a protein that plays a critical role in the biology of Epstein-Barr Virus (EBV), a virus associated with various malignancies and diseases, including nasopharyngeal carcinoma and lymphoproliferative disorders. EBNA1BP2 has been identified as an essential cofactor for the stability of EBNA1, a key viral protein that ensures the replication and persistence of the EBV genome in infected cells. The interaction between EBNA1 and EBNA1BP2 is vital for the virus's latent infection and contributes to its pathogenicity. Research into the recombinant expression of EBNA1BP2 provides insights into its structural and functional properties, facilitating the development of therapeutic strategies aimed at disrupting the EBV life cycle. Understanding the molecular mechanisms by which EBNA1BP2 contributes to EBV persistence and related diseases holds promise for advancing treatments for EBV-associated conditions. Moreover, the study of EBNA1BP2 can aid in elucidating the virus-host interactions that underpin EBV's ability to evade the immune response, further emphasizing its importance in virology and cancer research. With the increasing recognition of EBV's role in various diseases, the exploration of EBNA1BP2 as a target for therapeutic intervention is becoming increasingly relevant, opening new avenues for research and potential clinical applications.
